104 related articles for article (PubMed ID: 21625847)
21. The redox protein thioredoxin-1 (Trx-1) increases hypoxia-inducible factor 1alpha protein expression: Trx-1 overexpression results in increased vascular endothelial growth factor production and enhanced tumor angiogenesis.
Welsh SJ; Bellamy WT; Briehl MM; Powis G
Cancer Res; 2002 Sep; 62(17):5089-95. PubMed ID: 12208766
[TBL] [Abstract][Full Text] [Related]
22. siRNA targeting HIF-1alpha induces apoptosis of pancreatic cancer cells through NF-kappaB-independent and -dependent pathways under hypoxic conditions.
Chen C; Yu Z
Anticancer Res; 2009 Apr; 29(4):1367-72. PubMed ID: 19414389
[TBL] [Abstract][Full Text] [Related]
23. A noninvasive approach for assessing tumor hypoxia in xenografts: developing a urinary marker for hypoxia.
Nelson DW; Cao H; Zhu Y; Sunar-Reeder B; Choi CY; Faix JD; Brown JM; Koong AC; Giaccia AJ; Le QT
Cancer Res; 2005 Jul; 65(14):6151-8. PubMed ID: 16024616
[TBL] [Abstract][Full Text] [Related]
24. Hypoxia-inducible factor (HIF)-3alpha is subject to extensive alternative splicing in human tissues and cancer cells and is regulated by HIF-1 but not HIF-2.
Pasanen A; Heikkilä M; Rautavuoma K; Hirsilä M; Kivirikko KI; Myllyharju J
Int J Biochem Cell Biol; 2010 Jul; 42(7):1189-200. PubMed ID: 20416395
[TBL] [Abstract][Full Text] [Related]
25. Gene transfer of antisense hypoxia inducible factor-1 alpha enhances the therapeutic efficacy of cancer immunotherapy.
Sun X; Kanwar JR; Leung E; Lehnert K; Wang D; Krissansen GW
Gene Ther; 2001 Apr; 8(8):638-45. PubMed ID: 11320410
[TBL] [Abstract][Full Text] [Related]
26. Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer.
Wigerup C; Påhlman S; Bexell D
Pharmacol Ther; 2016 Aug; 164():152-69. PubMed ID: 27139518
[TBL] [Abstract][Full Text] [Related]
27. HIF-2alpha enhances beta-catenin/TCF-driven transcription by interacting with beta-catenin.
Choi H; Chun YS; Kim TY; Park JW
Cancer Res; 2010 Dec; 70(24):10101-11. PubMed ID: 21159632
[TBL] [Abstract][Full Text] [Related]
28. Stra13/DEC1 and DEC2 inhibit sterol regulatory element binding protein-1c in a hypoxia-inducible factor-dependent mechanism.
Choi SM; Cho HJ; Cho H; Kim KH; Kim JB; Park H
Nucleic Acids Res; 2008 Nov; 36(20):6372-85. PubMed ID: 18838394
[TBL] [Abstract][Full Text] [Related]
29. Hypoxia inducible factor-1: a novel target for cancer therapy.
Belozerov VE; Van Meir EG
Anticancer Drugs; 2005 Oct; 16(9):901-9. PubMed ID: 16162966
[TBL] [Abstract][Full Text] [Related]
30. New anticancer strategies targeting HIF-1.
Yeo EJ; Chun YS; Park JW
Biochem Pharmacol; 2004 Sep; 68(6):1061-9. PubMed ID: 15313402
[TBL] [Abstract][Full Text] [Related]
31. Treatment regimen determines whether an HIF-1 inhibitor enhances or inhibits the effect of radiation therapy.
Harada H; Itasaka S; Zhu Y; Zeng L; Xie X; Morinibu A; Shinomiya K; Hiraoka M
Br J Cancer; 2009 Mar; 100(5):747-57. PubMed ID: 19223896
[TBL] [Abstract][Full Text] [Related]
32. Design, synthesis, and structure-activity relationships of 1-ethylpyrazole-3-carboxamide compounds as novel hypoxia-inducible factor (HIF)-1 inhibitors.
Yasuda Y; Arakawa T; Nawata Y; Shimada S; Oishi S; Fujii N; Nishimura S; Hattori A; Kakeya H
Bioorg Med Chem; 2015 Apr; 23(8):1776-87. PubMed ID: 25773014
[TBL] [Abstract][Full Text] [Related]
33. Hypoxia inducible factor pathway inhibitors as anticancer therapeutics.
Burroughs SK; Kaluz S; Wang D; Wang K; Van Meir EG; Wang B
Future Med Chem; 2013 Apr; 5(5):553-72. PubMed ID: 23573973
[TBL] [Abstract][Full Text] [Related]
34. Cancer therapeutic agents targeting hypoxia-inducible factor-1.
Wang R; Zhou S; Li S
Curr Med Chem; 2011; 18(21):3168-89. PubMed ID: 21671859
[TBL] [Abstract][Full Text] [Related]
35. Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy.
Semenza GL
Trends Pharmacol Sci; 2012 Apr; 33(4):207-14. PubMed ID: 22398146
[TBL] [Abstract][Full Text] [Related]
36. Targeting hypoxia for sensitization of tumors to radio- and chemotherapy.
Ghattass K; Assah R; El-Sabban M; Gali-Muhtasib H
Curr Cancer Drug Targets; 2013 Jul; 13(6):670-85. PubMed ID: 23687923
[TBL] [Abstract][Full Text] [Related]
37. How can we overcome tumor hypoxia in radiation therapy?
Harada H
J Radiat Res; 2011; 52(5):545-56. PubMed ID: 21952313
[TBL] [Abstract][Full Text] [Related]
38. HIF-1 as a target for cancer chemotherapy, chemosensitization and chemoprevention.
Monti E; Gariboldi MB
Curr Mol Pharmacol; 2011 Jan; 4(1):62-77. PubMed ID: 20958262
[TBL] [Abstract][Full Text] [Related]
39. HIF repressors under chronic hypoxia.
Luo W; Wang Y
Aging (Albany NY); 2016 Mar; 8(3):418-9. PubMed ID: 26954058
[No Abstract] [Full Text] [Related]
40. Targeting the hypoxia pathway to treat pancreatic cancer.
Erickson LA; Highsmith WE; Fei P; Zhang J
Drug Des Devel Ther; 2015; 9():2029-31. PubMed ID: 25897209
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
